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Modelling Torsade de Pointes arrhythmias in vitro
in 3D human iPS cell-engineered heart tissue
Masahide Kawatou1,2, Hidetoshi Masumoto1,2, Hiroyuki Fukushima1, Gaku Morinaga1,3, Ryuzo Sakata2,
Takashi Ashihara4 & Jun K. Yamashita1
Torsade de Pointes (TdP) is a lethal arrhythmia that is often drug-induced, thus there is an
urgent need for development of models to test or predict the drug sensitivity of human
cardiac tissue. Here, we present an in vitro TdP model using 3D cardiac tissue sheets (CTSs)
that contain a mixture of human induced pluripotent stem cell (hiPSC)-derived cardiomyo-
cytes and non-myocytes. We simultaneously monitor the extracellular ﬁeld potential (EFP)
and the contractile movement of the CTSs. Upon treatment with IKr channel blockers, CTSs
exhibit tachyarrhythmias with characteristics of TdP, including both a typical polymorphic EFP
and meandering spiral wave re-entry. The TdP-like waveform is predominantly observed in
CTSs with the cell mixture, indicating that cellular heterogeneity and the multi-layered 3D
structure are both essential factors for reproducing TdP-like arrhythmias in vitro. This 3D
model could provide the mechanistic detail underlying TdP generation and means for drug
discovery and safety tests.
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Cardiac toxicity is the most crucial adverse event in drugdiscovery and development1–3. In particular, drug-induced arrhythmia is one of the most common causes
of drug withdrawal from the market4, 5. Torsade de Pointes
(TdP), a representative drug-induced lethal arrhythmia, is a
polymorphic ventricular tachycardia (VT) that is characterized by
a twisting wave appearance in electrocardiograms (ECGs) and
leads to ventricular ﬁbrillation and sudden death6. The ICH S7B
guidelines7, which are currently used for the non-clinical phar-
macological safety testing of human pharmaceuticals and include
information concerning integrated risk assessments, set QT
interval prolongation in ECGs as a major endpoint. This pro-
longation reﬂects the delayed ventricular repolarization and is a
cause of subsequent TdP.
In addition to in vivo animal tests using canine or monkey
under telemetry, the guidelines advocate using mammalian cell
lines that constitutively overexpress the human ether-a-go-go
related gene (hERG), which encodes the cardiac delayed-
rectifying K+ channel (IKr) (hERG test)7, 8. Human induced
pluripotent stem cell (hiPSC)-derived cardiomyocytes have cre-
ated the possibility of using human cells to test the arrhythmo-
genicity of drugs9, 10. However, single cell types (cardiomyocytes
alone) in two-dimensional (2D) culture-based methods only
display restricted abnormal electrical activities, such as the pro-
longation of ﬁeld potential duration (FPD) corresponding to the
QT interval in an ECG, and transient phenomena such as early
after depolarization and triggered activity11, 12. Additionally, 2D
culture methods fail to show the actual electrical activities of TdP,
which include sustained irregular electrical activity due to re-
entry of electrical excitation among neighboring cardiac cells.
More importantly, these methods fail to reproduce the abnormal
kinetics of TdP that occur in native three-dimensional (3D) heart
tissue. An in vitro 3D model with human cells that can reproduce
TdP has never been reported as far as we know. We hypothesized
that reproducing TdP in vitro might be possible if 3D heart tissue
could be generated from hiPSCs.
In the present study, we integrate our two unique technologies to
systematically induce various cardiovascular cells from hiPSCs13, 14
and to generate 3D tissue-like structures using a bioengineered cell
sheet technology14–17. Using these techniques, we generate an
in vitro drug-induced TdP model that recapitulates the actual
kinetics of TdP only with hiPSC-derived cell populations.
Results
Generation of 3D hiPSC-derived cardiac tissue sheets. First, we
tried to generate a 3D model with pure cardiomyocytes. Based on
our reported method13, 14, we prepared pure cardiomyocytes
from hiPSCs (836B3 line18). In brief, we differentiated hiPSCs
toward mesodermal cell lineages using deﬁned chemicals and
growth factors in a high-density 2D culture. We puriﬁed meso-
dermal cells (platelet-derived growth factor receptor type alpha-
positive) and then further differentiated the mesoderm cells into
cardiomyocytes. Highly pure cardiac troponin T-positive cardi-
omyocytes (96.3± 2.5%; ﬂow cytometry) were successfully
obtained (Supplementary Fig. 1a–d). The induced cardiomyocytes
were mostly ventricular cardiac muscle form of myosin light
chain 2 (MLC2V)-positive ventricular-type cardiomyocytes [97.3
± 1.3% (n= 4)] (Supplementary Fig. 1e, f). Then, we
generated a 3D cell sheet structure purely from the cardiomyo-
cytes. We re-cultured the cardiomyocytes on temperature-
responsive culture dishes (Supplementary Fig. 1g). After 4 days
of culture at 37 °C, we reduced the culture temperature to room
temperature and collected the cells as self-pulsating cell sheets
exclusively consisting of cardiomyocytes (94.7± 3.6% of total
cells; ﬂow cytometry). We placed the pure cardiomyocyte sheets
on multi-electrode array probes to measure the EFP after
exposure to E-4031, which is a representative IKr channel blocker
that typically exhibits cardiotoxicity by delayed ventricular
repolarization and QT prolongation on ECG, marking
eventual TdP. Even though we observed dose-dependent FPD
prolongation, TdP-like waveforms were never induced in the
pure cardiomyocyte sheets, even with high doses of E-4031 up to
2 μM, which speciﬁcally block IKr channels (Supplementary
Fig. 2)19, 20.
Considering the pathological ﬁndings of cardiomyopathy
patients with serious ventricular arrhythmia, the heart is
deformed and consists of fewer cardiomyocytes and more ﬁbrotic
tissue compared with healthy individuals21–23. Thus, we
hypothesized that increasing the cellular heterogeneity within
the heart tissue constructs may better reproduce the arrhythmo-
genic microenvironment. We planned to reduce the cardiomyo-
cyte component within the cell sheets by including hiPSC-derived
non-myocytes. We induced CD90-positive (98.9± 0.2%; ﬂow
cytometry) mesenchymal cells (also positive for vimentin,
α-smooth muscle actin, and calponin via immunostaining)
(Supplementary Fig. 3a–g). Mesenchymal cells represent a
non-myocyte population within the heart, which include smooth
muscle cells and cardiac ﬁbroblasts. We generated cell sheets in
which cardiomyocytes and non-myocytes were evenly mixed to
prepare CTSs with heterogeneous cellular compositions (Supple-
mentary Fig. 3h). The CTSs consisted of cardiomyocytes (52.7±
10.0% of total cells) and mesenchymal cells (39.9± 9.0%)
according to ﬂow cytometry (Supplementary Fig. 3i). Confocal
immunostaining images of CTSs indicated a heterogeneous
cellular composition and allocation (Fig. 1a, b). Cross-sectional
images revealed that the CTSs had a multi-layered 3D cellular
structure of 5–6 cell layers, verifying that the CTSs were
constructed as 3D structures (Fig. 1c, d and Supplementary
Movie 1). Even after forming 3D structures, the cell viability
within the CTSs was extremely high (Supplementary Fig. 4), and
no sign of hypoxia was detected based on HIF1α expression
(Supplementary Fig. 5). The expression levels of several ion
channel genes in the CTSs were comparable with those in adult
human heart, except KCNJ2 (coding Kir2.1; related to IK1
current) and SCN5A (coding NaV1.5; related to INa current),
suggesting that the CTSs were not fully matured adult cardiac
tissue (Supplementary Fig. 6)24, 25. The EFP of the CTSs
measured on a multi-electrode array indicated comparable
electrical waveforms at all electrodes (Fig. 1e, f). An electrical
propagation map showed a synchronized, unidirectional propa-
gation pattern (Fig. 1g). Thus, we generated 3D heterogeneous
heart tissues entirely from hiPSCs that act as an in vitro beating
cardiac wall model.
Drug-induced TdP-like EFP waveforms in CTSs. Next, we
investigated the occurrence of drug-induced TdP using our
in vitro model. We recorded the EFP of CTSs and examined the
response toward E-4031. E-4031 treatment (up to 100 nM) led to
dose-dependent prolongation of the FPD (Fig. 2a–c), indicating
that our CTSs respond to E-4031 in a manner that is comparable
to hiPSC-derived single cardiomyocytes11 and pure cardiomyocyte
sheets (Supplementary Fig. 2). The beat rate; inter-spike intervals,
which represents the R-R interval in ECGs; conduction velocity;
and the ﬁrst peak amplitude were all unaffected by the
E-4031 concentration (Table 1). In addition to FPD prolongation,
an irregular waveform was observed at higher doses of E-4031
(higher than 100 nM) (Fig. 2d). We ﬁnally observed a sustained
waveform of tachyarrhythmia (Fig. 2e) and a characteristic TdP-
like pattern with polymorphic twisting waveform (Fig. 2f and
Supplementary Movie 2). These results strongly suggest that TdP-
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like arrhythmias can be induced in our 3D CTS model. We further
tried to conﬁrm the actual cell behavior as tachyarrhythmia.
Visualization of spiral wave re-entry in TdP model. Spiral wave
re-entry is a considerable mechanism of lethal tachyarrhythmia
(Fig. 3a)26–29. This theory assumes two representative patterns of
the spiral wave re-entry in tachyarrhythmia: an anchoring (sta-
tionary) pattern of the spiral wave center, which results in sus-
tained monomorphic VT, and a meandering (chaotically moving
around) pattern of the spiral wave center, which results in
polymorphic VT such as TdP. To visualize and conﬁrm the
occurrence of TdP-like arrhythmias as 2D spiral waveforms of the
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Fig. 1 Characterization of heterogeneous 3D cardiac tissue sheets (CTSs). a Representative confocal microscopic image of a whole CTS that was
immunostained for cTnT (cardiomyocytes, red), CD90 (mesenchymal cells, green), and DAPI (nuclei, blue). b High-magniﬁcation image of a horizontal
cross-section (see Supplementary Movie 1). cTnT (red), CD90 (green), and DAPI (blue). c Confocal immunostaining of a vertical cross-section. cTnT
(red), CD90 (green), and DAPI (blue). d Confocal immunostaining of a vertical cross-section. DAPI (white). e Macroscopic appearance of a CTS set on a
multi-electrode array probe. Arrow: CTS. Black arrowhead: a reference electrode (four reference electrodes in total). White arrowhead: main electrodes
(multi-electrode array). f Representative EFP waveforms obtained from each electrode. g Representative electrical propagation map. Propagation from the
lower left corner towards the upper right direction. cTnT, cardiac troponin-T; DAPI, 4′,6-diamidino-2-phenylindole. Scale bars: 25 μm in b, 50 μm in c, d,
and 1 mm in e
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Table 1 Parameters of ﬁeld potential measurements after E-4031 treatment in CTSs with 50% cardiomyocytes (±s.d., n= 4)
Beat rate (/min) ISI (ms) FPD (ms) First peak amplitude (μV) Conduction velocity (mm/s)
0 nM 28± 12 2591± 1244 376± 172 498± 211 43± 24
0.3 nM 27± 12 2656± 1265 384± 179 511± 211 44± 24
3 nM 26± 14 2743± 1343 400± 183 524± 221 46± 22
10 nM 28± 14 2609± 1284 422± 176 537± 217 46± 24
30 nM 31± 14 2346± 1094 424± 152 541± 213 43± 26
100 nM 29± 13 2412± 1078 482± 154 536± 210 48± 19
1 μM N/A N/A N/A 522± 218 42± 19
2 μM N/A N/A N/A 540 (n= 2) 53 (n= 2)
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Fig. 2 Drug-induced TdP-like EFP waveforms in CTSs. a EFP waveforms in response to E-4031 (IKr channel blocker). b Overlaid EFP waveforms at each
E-4031 dosage. FPD prolongation is observed. c Relative change in FPD after E-4031 treatment (±s.d., n= 4). d Representative transient change of EFP
waveforms at an early stage after E-4031 treatment (1 μM). e Representative monomorphic ventricular tachycardia-like waveform after E-4031 treatment
(1 μM). f Representative polymorphic ventricular tachycardia TdP-like waveform after E-4031 treatment (1 μM)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01125-y
4 NATURE COMMUNICATIONS |8:  1078 |DOI: 10.1038/s41467-017-01125-y |www.nature.com/naturecommunications
imaging system (Motion Vector Prediction; Sony, Tokyo, Japan)
that captures the magnitude of beating cell motion (contraction
and relaxation) as biphasic waves (Supplementary Fig. 7) and
visualized computed 2D images of the projection map. We
simultaneously recorded EFP and cell motion imaging and
successfully detected the appearance of both spiral wave re-entry
patterns. Before E-4031 treatment, we conﬁrmed unidirectional
biphasic wave propagation with simple contraction-relaxation
movements of synchronized beating (Fig. 3b and Supplementary
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Fig. 3 Drug-induced TdP in CTSs visualized by Motion Vector Prediction. a Schematic images of two re-entrant arrhythmia patterns for the spiral wave
re-entry theory. Anchoring pattern and Meandering pattern. b Representative normal beats visualized by motion vector prediction (captured from
Supplementary Movie 3). Unidirectional biphasic wave propagation (E-4031, 0 nM). c Representative anchoring spiral wave re-entry visualized by motion
vector prediction (captured from Supplementary Movie 4). Anchoring spiral wave re-entry motion propagation (E-4031, 1 μM). d Schematic image related
to c. e Representative meandering spiral wave re-entry with simultaneous recording of EFP and cell motion (E-4031, 1 μM). Cell motion is visualized by
motion vector prediction (captured from Supplementary Movie 6). White circles: spiral wave center. EFP shows TdP-like waveform. The numbers in the
upper and lower panels indicate the same time points. Note that similar spiral wave center movement (ex: 2 to 3 and 5 to 6) causes similar EFP
polymorphisms. f Tracing of the spiral wave centers. Representative anchoring of spiral wave re-entry with the corresponding monomorphic ventricular
tachycardia-like EFP waveform (E-4031, 1 μM) and representative meandering (drifting) of spiral wave re-entry (upper) with the corresponding TdP-like
EFP waveform (E-4031, 2 μM). White circles: center of spiral wave. Black lines: trace of the center. Scale bars: 1 mm
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re-entry waveforms (Fig. 3c, d and Supplementary Movie 4). A
transition process from the unidirectional waveform to spiral
wave re-entry was also observed (Supplementary Movie 5).
Simultaneous recording of EFP and cell motion imaging suc-
cessfully exhibited polymorphic waveforms of EFP together with
2D spiral cell motion that clearly shows meandering of the spiral
wave center (Fig. 3e, f and Supplementary Movie 6–8). These
features exemplify the meandering pattern of the spiral wave re-
entry that is related to TdP. In contrast, for the anchoring pattern,
the center was almost pinned to the 2D motion projection map
and was accompanied by monomorphic VT-like EFP (Fig. 3f and
Supplementary Movie 8). Voltage-sensitive dye staining of the
CTSs also revealed a spiral wave re-entry pattern in the electrical
voltage oscillation after E-4031 treatment, indicating that the
spiral wave re-entry represented both the kinetic and the electrical
behavior of the CTSs (Supplementary Fig. 8 and Supplementary
Movie 9). The calculated round frequency (round per second) of
the tachyarrhythmias in our CTSs was 2.5± 0.8 Hz (n= 4) in
regular sustained tachyarrhythmia and 2.8± 0.3 Hz (n= 4) in
TdP-like waveforms. The round frequency was> 8-fold higher
than that in a previous report of a re-entrant arrhythmia model
using human iPSC-derived cardiomyocytes10. Thus, drug-
induced TdP-like arrhythmias were successfully reproduced
in vitro with our hiPSC-derived CTS model.
Validation of TdP-like waveform in CTSs. We conﬁrmed the
appearance of TdP-like arrhythmias in another cell line and using
other drugs. We used commercially available hiPSC-derived
cardiomyocytes, MiraCell® (Takara Bio Inc., Kusatsu, Japan),
which were induced from Cellartis human iPS cell line 12 (Cel-
lartis, Göteborg, Sweden), to generate CTSs. These CTSs exhib-
ited similar TdP-like waveforms and meandering spiral wave re-
entry in response to as little as 10 nM E-4031 (Supplementary
Fig. 9 and Supplementary Movie 10). We also observed short-
long-short sequences in the initiation of TdP-like waveforms,
which is a representative pattern of the initiation of TdP in
clinical settings (Supplementary Fig. 9b)30. We tested cisapride, a
gastroprokinetic agent withdrawn from the U.K. and U.S. markets
because of reported heart rhythm abnormalities, including sud-
den death that was possibly related to TdP31. Cisapride caused
TdP-like waveforms with a high induction rate in CTSs con-
stituting a mixture of cardiomyocytes and non-myocytes (9 of 15;
60%), but no induction was observed in pure cardiomyocyte
sheets (Supplementary Fig. 10a, b). Similar TdP-like waveforms
were observed after the addition of ﬂecainide, which is clinically
reported to induce TdP due to QT prolongation (Supplementary
Fig. 10c)32. These results indicate that the induction of TdP-like
EFP waveforms can be reproduced in CTSs with relevance to the
clinical ﬁndings.
We also tried to induce TdP-like waveforms under CTS pacing.
Under 1-Hz electrical stimulation, the CTSs pulsated in
accordance with the pacing frequency. Administration of
E-4031 dose-dependently elongated the FPD, as observed in
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Fig. 4 Drug-induced TdP-like EFP waveforms in CTSs under 1-Hz pacing. a Overlaid EFP waveforms at each E-4031 dosage under 1-Hz pacing. FPD
prolongation is observed. b Relative change in FPD after E-4031 treatment under 1-Hz pacing (±s.d., n= 4). c Representative TdP-like waveforms after
E-4031 treatment (1 μM) under 1-Hz pacing. The white arrowhead shows transient pacing failure that is not followed by electrical excitation of the CTS. The
orange arrowhead shows pacing success followed by electrical excitation of CTS. The ﬁrst pacing failure resulted in short-long-short sequence-like
waveforms
Table 2 Change of ﬁeld potential durations after E-4031
treatment in 1-Hz paced CTSs with 50% cardiomyocytes
(±s.d., n= 4)
Beat rate (/min) FPD (ms)
0 nM 60 199± 22
0.3 nM 60 198± 22
3 nM 60 201± 19
10 nM 60 213± 16
30 nM 60 229± 13
100 nM 60 244± 14
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we successfully induced TdP-like waveforms in most of the paced
CTSs by E-4031 administration (5 of 7; 71%) (Fig. 4c). TdP-like
waveforms were triggered by pacing failures that resulted in the
formation of short-long-short sequence-like patterns. These
results indicate that TdP-like phenomena can be reproduced
under comparable action potential durations with pacing in our
model.
Sine qua non for TdP generation in vitro. Because these results
suggest that cellular heterogeneity and 3D structure are important
for the reproduction of TdP-like arrhythmias, we next tried to
dissect the importance of cellular heterogeneity and 3D structure
in the pathogenesis of TdP by manipulating these parameters in
the constructs. We examined four classes of 3D CTSs with dif-
ferent cardiomyocyte composition ratios (25, 50, 75, and 100%) in
response to E-4031 treatment (Supplementary Fig. 11a). Whereas
neither stationary re-entry waveform nor TdP-like waveform was
induced on cell sheets with 100% cardiomyocytes (C100; no
heterogeneity), as shown above (Supplementary Fig. 2), all CTSs
with cellular heterogeneity (C25, C50, C75) exhibited TdP-like
waveforms, with the highest incidence (80%) at 50% cardio-
myocytes (C50) (Fig. 5a). In contrast, in 2D culture conditions
with 1–2 cell layers (Supplementary Fig. 11b), TdP-like wave-
forms were observed in only 30% of 2D culture condition, even
with high heterogeneity (C50) (Fig. 5a). Similar results were
obtained in CTSs that were constructed with MiraCell® cardio-
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Fig. 5 Sine qua non for TdP generation in vitro. a Induction rates of TdP-like waveform in CTSs of different heterogeneities and dimensions. C100, cells or
sheets with 100% cardiomyocytes. C75, cells or sheets with 75% cardiomyocytes. C50, cells or sheets with 50% cardiomyocytes. C25, sheets with 25%
cardiomyocytes. CMs, cardiomyocytes. Fisher’s exact test *p< 0.05, **p< 0.01 and ***p< 0.001. b Relationship of TdP-like waveform incidence with cell
heterogeneity and dimension. c A putative mechanism for the emergence of TdP. Heterogeneity and dimension enhance the initiation of micro re-entry
events and the maintenance of meandering spiral wave centers, respectively, in CTSs. Cellular heterogeneity hampers electrical conduction and detours the
propagation direction. The 3D structure eliminates the coarse structures that are present in 2D layers and provides appropriate heterogeneity for a
functional center of spiral wave re-entry
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like waveforms was signiﬁcantly higher in 3D CTSs compared
with 2D conditions (p= 0.0344, C50; p= 0.0302, C75 Fisher’s
exact test), indicating that the coincidence of cellular hetero-
geneity and 3D structure is required and sufﬁcient for the
emergence of TdP-like arrhythmias in our in vitro model (Fig. 5a,
b and Supplementary Fig. 12a, b). The beat-to-beat variability of
the repolarization in sequential recordings of the ECG or EFP is a
surrogate risk marker for ventricular arrhythmia33, 34. We
quantiﬁed the variability of FPD in 1 Hz-paced CTSs of different
cardiomyocyte composition ratios. The short-term variability
(STV) and the coefﬁcient of variation in C50 were signiﬁcantly
higher than those in C100 (Supplementary Fig. 13), further
supporting that cell heterogeneity increased the risk of TdP.
Connexin 43 (Cx43) immunostaining for gap junctions in the
CTSs showed that Cx43 expression was predominantly localized
in the cardiomyocyte region within the CTSs (Supplementary
Fig. 14). Thus, cellular heterogeneity that hampers electrical
conduction and detours the propagation direction may relate the
formation of micro-re-entry events that could initiate TdP
(Fig. 5c)35.
Three-dimensional structure as pathogenesis of TdP. An
apparent difference between the two types of spiral wave re-entry
as models of VT-like and TdP-like arrhythmias is the movement
of the spiral wave center. Whereas VT-like spiral wave re-entry
was observed in a 2D in vitro model in a previous study10,
apparent TdP occurrence was not reported. We speculated that
the 3D structure is more effective at reproducing the meandering
spiral wave re-entry, making it a more reliable model of TdP. In
the previous study10, VT-like spiral wave re-entry was stably
induced after the generation of an acellular region in 2D cultured
human iPS cell-derived cardiomyocytes. The wavefronts went
around the anatomically ﬁxed obstacle, conﬁrming that mean-
dering will never occur in this model. To achieve meandering of
the spiral wave center, functional, rather than anatomically ﬁxed,
centers (i.e., excitable but non-excited areas) with appropriate
heterogeneity should be broadly generated throughout the CTS. If
too large an assembly of cardiomyocytes or non-myocytes
(“coarse structure”) exists, the spiral wave re-entry would be
expected to disappear. To conﬁrm this hypothesis, we conducted
Z-stacking of four serial cross-sectional layers of CTSs after
Cx43 staining. The coefﬁcient variant of Cx43 expression in each
layer was reduced after the Z-stacking (Supplementary Fig. 14b).
This result indicates that the 3D structure should be beneﬁcial for
minimizing the presence of coarse structures and broadly provide
appropriate heterogeneity for a functional center of spiral wave
re-entry in CTSs, resulting in sustained TdP-like arrhythmias.
Thus, cellular heterogeneity and 3D structure are two sine qua
non for TdP arrhythmias because they initiate and maintain the
meandering spiral wave center, respectively (Fig. 5c)19, 35.
Discussion
In the present study, we generated an in vitro TdP model by
efﬁciently integrating current technological progress in (1) stem
cell biology, (2) tissue engineering, and (3) live cell imaging. (1)
Our unique hiPSC differentiation method toward cardiovascular
cell populations13, 14 is amenable to collecting highly pure cardiac
cellular populations for precise modeling and generating an
in vitro model entirely from hiPSCs. (2) We also employed a
bioengineered cell sheet technology based on a temperature-
responsive culture surface14, which enabled us to generate 3D
tissue structures without special equipment or technological
demand. (3) Beyond a 1D linear depiction of FPD (resembling
ECG), we could visualize 2D live images of actual cell behavior
with a high-precision live cell imaging system. The strong signals
detected by this new cell imaging system allowed us to clearly
visualize wavefronts that represent states just after depolarization
and wave tails that represent the end of repolarization (Supple-
mentary Movie 11) and to successfully conﬁrm the meandering of
the spiral wave center as the cellular kinetics. To our knowledge,
the present study is the ﬁrst to directly visualize the occurrence of
TdP-like arrhythmias as actual biological responses in human
tissue. 3D heart tissue modeling is expected to change the
understanding of TdP. The new evidence here that not only
electrophysiological phenomena but also structural features
contribute to TdP generation would provide a novel concept in
TdP pathogenesis. In vitro 3D tissue modeling with human
pluripotent stem cells can be extended to reproduce a variety of
tissue or organ responses including patient iPSC research. Con-
sidering the heterogeneity of healthy and diseased human hearts
regarding cellular components36, individual cell size and/or
maturation level, being able to manipulate various parameters
including disease cell components would provide further under-
standing of cardiac pathophysiology and help explore new
therapies and drugs for heart disease
Methods
Human iPSC culture and differentiation. Human iPSCs made with 6-factor
episomal plasmid vector (Oct3/4, Sox2, Klf4, L-Myc, LIN28 and Glis1) (line:
836B3)18 (passage 24–34) and 4-factor (Oct3/4, Sox2, Klf4 and c-Myc) (line:
201B6)37 (passage 38–48) served as pluripotent cells, which were originally
established from skin ﬁbroblasts at Center for iPS Cell Research and Application,
Kyoto University, Kyoto, Japan. The 836B3 line was used in all experiments unless
stated otherwise.
These human iPSCs were adapted and maintained on thin-coat Matrigel
(Growth factor-reduced; 1:60 dilution; BD, Franklin Lakes, USA) in mouse
embryonic ﬁbroblast conditioned medium (MEF-CM) supplemented with
4–5 ng/mL human basic ﬁbroblast growth factor (bFGF; WAKO, Osaka,
Japan)13, 38. Cells were passaged as small clusters once every 4–6 days using CTK
solution [0.1% collagenase IV, 0.25% trypsin, 20% knockout serum replacement,
and 1 mM CaCl2 in phosphate-buffered saline (PBS)].
Cardiovascular cell differentiation was induced as shown in Supplementary
Figs. 1a and 3a. Cells were detached by 3–5 min incubation with Versene (0.48 mM
EDTA; Thermo Fisher Scientiﬁc, Waltham, USA) and seeded onto Matrigel-coated
6-multiwell plate at 7.0-8.0 x 105 cells/well in MEF-CM with 4-5 ng/mL bFGF for
2–3 days before induction. Cells were covered with Matrigel (1:60 dilution) on the
day before induction. To induce mesodermal differentiation, we replaced
MEF-CM with RPMI + B27Ins(−) medium (RPMI1640, 2 mM L-glutamine, × 1
B27 supplement without insulin) supplemented with 100 ng/mL activin A (ActA;
R&D, McKinley Place NE, USA) for 24 h, followed by 10 ng/mL human bone
morphogenetic protein 4 (BMP4; R&D) and 10 ng/mL bFGF.
For cardiomyocyte differentiation, cells were dissociated by incubation with
Accumax (Innovative Cell Technologies, San Diego, USA) 5 days after induction,
and platelet-derived growth factor receptor-α (PDGFRα)-positive cells were
puriﬁed with a magnetic activated cell sorter (MACS) (Miltenyi Biotec, Bergisch
Gladbach, Germany) using anti-PDGFRα antibody conjugated with
allophycocyanin (APC) (R&D) and anti-APC microbeads (Miltenyi)
(Supplementary Fig. 1a, b). Puriﬁed PDGFRα+ cells were replated onto a Matrigel-
coated 6-multiwell plate at 2.5–3.0 × 106 cells/well with 3 mL RPMI1640 medium
containing 2 mM L-glutamine, 10% fetal bovine serum (FBS) supplemented with
10 μM XAV939 (Merck KGaA, Darmstadt, Germany), 5 μM IWP4 (STEMGENT,
Lexington, USA) and a ROCK (Rho kinase) inhibitor (Y-27632, WAKO; 20 μM).
After 1 day in culture, 2 mL of the same medium was added. After 1 more day in
culture, the culture medium was replaced with RPMI + B27Ins(+) medium
(RPMI1640, 2 mM L-glutamine, ×1 B27 supplement with insulin) supplemented
with 0.25 μM XAV939, 0.125 μM IWP4 and 20 μM Y-27632. On day 9 after
induction, the culture medium was replaced with RPMI + B27Ins(+) medium. The
culture medium was refreshed every other day. Beating cells appeared on days
9–12.
For mesenchymal cell differentiation, cells were dissociated by incubation with
Accumax 4 days after induction, and PDGFRα+ cells were puriﬁed with a MACS as
described above (Supplementary Fig. 3a, b). Puriﬁed PDGFRα+ cells were replated
onto a Matrigel-coated 6-multiwell plate at 2.0–2.5 × 106 cells/well with 3 mL of
RPMI1640 medium containing 2 mM L-glutamine, 10% FBS and 20 μM Y-27632.
After 2 days in culture, the culture medium was replaced with RPMI1640 medium
containing 2 mM L-glutamine and 10% FBS. The culture medium was refreshed
every other day.
Human iPS cell-derived cardiac tissue sheet formation. Cardiomyocytes
(30–60 days after differentiation) were dissociated by incubation with 0.25%
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trypsin (Thermo Fisher Scientiﬁc), and mesenchymal cells (15–45 days after dif-
ferentiation) were dissociated by incubation with Accumax (Innovative Cell
Technologies).
Cryopreserved hiPSC-derived cardiomyocytes (MiraCell® cardiomyocytes from
ChiPSC12) (Takara Bio Inc., Kusatsu, Japan) were prepared according to the
manufacturer’s protocol. The cells were thawed in thawing medium (Takara Bio
Inc.), plated on 50 μg/mL ﬁbronectin-coated 6-well tissue culture plates (2.0–2.7 ×
106 cells/well), and cultured in maintenance medium (Takara Bio Inc.). After two
days of culture, the cells were dissociated by incubation with 0.25% trypsin.
For CTSs consisting of pure cardiomyocytes, the cardiomyocytes were plated
onto a 0.1% gelatine-coated 48-multiwell UpCell® at 6.0 × 105 cells/well with 700
μL attachment medium [AM; alpha minimum essential medium (αMEM; Thermo
Fisher Scientiﬁc) supplemented with 10% FBS, 5 × 10−5 M of 2-mercaptoethanol,
50 units/mL penicillin and 50 μg/mL streptomycin] containing 50 ng/mL VEGF165
and 10 μM Y-27632. After 4 days in culture, the cells were moved to room
temperature. Within 30 min, cells detached spontaneously and ﬂoated in the
medium as 3D CTS.
For CTSs consisting of cardiomyocytes and mesenchymal cells, the cells were
mixed and plated as above. After 4 days in culture, the cells were moved to room
temperature. Within 30 min, cells detached spontaneously and ﬂoated in the
medium as 3D CTS. CTSs that had holes or macroscopic irregularities were
excluded from further evaluation.
Flow cytometry. During hiPSC differentiation and CTS generation, cells were
dissociated by incubation with Accumax and stained with anti-PDGFRα antibody
conjugated with APC (1:40, R&D) or anti-CD90 conjugated with APC (clone 5E10,
1:200, BioLegend, San Diego, USA). To eliminate dead cells, cells were stained with
LIVE/DEAD ﬁxable Aqua dead cell staining kit (Thermo Fisher Scientiﬁc). Cell
surface marker staining was performed in PBS with 5% FBS. For intracellular
proteins, staining was performed on cells ﬁxed with 4% paraformaldehyde (PFA) in
PBS. Cells were stained with the anti-cardiac isoform of Troponin-T (cTnT, clone
13211, 1:150 Thermo Fisher Scientiﬁc) labeled with Alexa-488 using Zenon tech-
nology (Thermo Fisher Scientiﬁc). The staining was performed in PBS with 5% FBS
and 0.75% saponin (Sigma-Aldrich, St. Louis, USA). Stained cells were analyzed on
an Aria II ﬂow cytometer (BD, Franklin Lakes, USA). Data were collected from at
least 5000 events and analyzed with DIVA software (BD).
Histological analysis. For immunoﬂuorescence staining, cardiomyocytes and
mesenchymal cells were ﬁxed with 4% PFA. The cells were treated with Protein
Block Serum-Free (DAKO, Glostrup, Denmark) and incubated overnight with
primary antibodies at 4 °C. Cardiomyocytes were stained for cTnT (anti-cardiac
isoform of cTnT, Thermo Fisher Scientiﬁc; 1:500), myosin light chain 2V (Pro-
teintech, Rosemont, USA; 1:200) and myosin light chain 2A (Synaptic Systems
GmbH, Göttingen, Germany; 1:400). Mesenchymal cells were stained for CD90
(BioLegend; 1:100), vimentin (Abcam, Cambridge, UK; 1:400), alpha-smooth
muscle actin (Sigma-Aldrich, 1:500) and calponin (Abcam, 1:250). Anti-mouse
Alexa 546 (Thermo Fisher Scientiﬁc, 1:500), anti-mouse Alexa 488 (Thermo Fisher
Scientiﬁc, 1:400), anti-rabbit Alexa 488 (Thermo Fisher Scientiﬁc, 1:400), or anti-
rabbit Alexa 647 (Thermo Fisher Scientiﬁc, 1:200) was used as a secondary anti-
body. Then, 4′,6-diamidino-2-phenylindole (DAPI; Nacalai Tesque, Kyoto, Japan)
was used to stain the cell nuclei. Stained cells were photographed with a confocal
microscope (Zeiss LMS 700, Carl Zeiss, Oberkochen, Germany) or all-in-one
ﬂuorescence microscopic system (Biorevo BZ-9000, Keyence, Osaka, Japan).
To count MLC2V-positive cells, four random views were selected from
MLC2V-, MLC2A- and DAPI-stained sections (×200, original magniﬁcation), and
the number of MLC2V-positive cells was counted in each view with Biorevo BZ-
9000.
CTS immunoﬂuorescence staining was performed similarly. cTnT (Thermo
Fisher Scientiﬁc; 1:500) and CD90 (BioLegend; 1:100) were used as primary
antibodies. Anti-mouse Alexa 546 (1:500) and anti-rabbit Alexa 488 (Thermo
Fisher Scientiﬁc, 1:400) were used as secondary antibodies. For Cx43 staining,
cTnT (Thermo Fisher Scientiﬁc; 1:500) and Cx43 (Sigma-Aldrich) (1:200) were
used as primary antibodies. Anti-mouse Alexa 546 (1:500) and anti-rabbit Alexa
488 (Thermo Fisher Scientiﬁc) (1:400) were used as secondary antibodies. CTSs
were stained with anti-human CD90 conjugated with Alexa 647, 1:100
(BioLegend). The stained sheets were photographed with a Nikon A1R MP
(Multiphoton + N STORM) (Nikon, Tokyo, Japan) or Zeiss LMS 700 (Carl Zeiss).
To measure the coefﬁcient of variation in Cx43 intensity, we selected four serial
cross-sectional layers (5-µm intervals) and an overlaid view ( × 1000, original
magniﬁcation) and calculated the coefﬁcient of variation of intensity in line pixels
(n= 240) in each layer with ImageJ (U. S. National Institutes of Health, Bethesda,
USA). Line pixels with no intensity were excluded from the analysis. Coefﬁcients of
variation values were calculated with the following equation:
Coefficient of variation ¼ standard deviation intensityð Þ=mean intensityð Þ ´ 100 %ð Þ
Measurement of EFP and drug treatment. EFPs were measured with the MED
system (Alpha MED Scientiﬁc, Osaka, Japan) using a Multi-electrode device
(MED) probe with 64 planer 50 μm square microelectrodes arranged in an
8 × 8 grid at 150-μm intervals (MED-P515A).
For 3D CTSs, the probe was sterilized with 70% ethanol and ultraviolet
irradiation and coated with 0.1% gelatine (Sigma-Aldrich) before use. A 3D CTS
was spread onto the MED probe. The medium was aspirated, and the CTS was
incubated at 37 °C. After at least 180 min, medium was added, and the CTS was
incubated with alpha minimum essential medium (αMEM) supplemented with
10% FBS, 5 × 10−5 M 2-mercaptoethanol, 50 units/mL penicillin, 50 μg/mL
streptomycin, 50 ng/mL VEGF165, and 10 μM Y-27632 for 2 days. Half of the
medium was changed every 2 days. Stable spontaneous EFPs were recorded from
3 days to 21 days after the initial placement.
For 2D culture, the probe was sterilized as above and coated with 50 μg/mL
ﬁbronectin (BD) before use. A total of 3 × 104 cells in 2 μL of medium was spread
onto the MED probe and incubated at 37 °C. The rest of the procedure was
performed as described above.
We measured EFPs according to a previous report with some modiﬁcations11.
Samples were equilibrated for at least 30 min in a CO2 incubator in 2 mL of fresh
medium prior to the measurements. After equilibration, the MED probes were
maintained at 37 °C with thermo-control systems and covered with a lid through,
which the gas was aerated (O2:CO2:N2= 20%:5%:75%). EFPs from spontaneously
beating samples or 1-Hz paced samples were ﬁltered with a vessel with a 1–1000 Hz
bandpass ﬁlter using the MED64 System. For stable pacing, samples were
stimulated with 2 volt (V) and paced from several microelectrodes. FPD was
deﬁned as the interval from the ﬁrst peak (depolarization) to the second peak
(repolarization). After recording the basal state, 2 μL dimethyl sulfoxide (DMSO;
Wako) was added, and EFPs were recorded for 10 min. Then, the IKr channel
blockers E-4031 (Wako), cisapride (Sigma-Aldrich), or the sodium and IKr channel
blocker ﬂecainide (Sigma-Aldrich) were added to obtain the target concentrations,
and EFPs were recorded in the same manner as the recordings of DMSO treatment.
For E-4031, seven drug concentrations (0.3 nM, 3 nM, 10 nM, 30 nM, 100 nM, 1
μM, and 2 μM) were selected to evaluate dose-dependent effects. For cisapride,
seven drug concentrations (3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 μM and 2 μM)
were selected. For ﬂecainide, ﬁve drug concentrations (0.03, 0.1, 0.3, 1, and 50 μM)
were selected. At each concentration, the EFP was recorded for 10 min and the FPD
values from the last 30 beats were averaged and used as the dataset for FPD and
waveform analysis39.
EFPs were processed with MED64 Mobius software (Alpha MED Scientiﬁc)
(Fig. 1f). Beat rate, the inter-spike interval (msec), FPD (msec), and the amplitude
of the initial sharp positive and negative deﬂection (ﬁrst peak; μV) were
measured40.
The electrical propagation map visualization software was produced by Alpha
MED Scientiﬁc as an application that utilizes Excel 2007 (Microsoft, Redmond,
USA). The microelectrode with the earliest negative peak potential was set to time
zero, and the negative peak timing of the other microelectrodes was measured. The
intervals between the negative peak timing of time zero and each electrode were
calculated and virtually visualized as a propagation-mapping image (Fig. 1g).
Conduction velocities were calculated from the distance and propagation time
between time zero electrode and the maximum time electrode.
To measure STV and the coefﬁcient of variation on EFP, we considered the
effect of noise-induced transitions. We selected waveforms at three channels with
the lowest noise among the 64 channels under 1 Hz pacing. The FPD values from
the 30 beats were averaged in the selected three channels and used to calculate STV
and the coefﬁcient of variation. STV and the coefﬁcient of variation values were
calculated with the following equations:
STV ¼
X





Coefficient of variation ¼ standard deviation FPDð Þ=mean FPDð Þ ´ 100 %ð Þ ð2Þ
Deﬁnition of Torsade de Pointes (TdP) -like waveform on EFP. TdP-like
waveforms satisﬁed the following two criteria.
● A continuous and characteristic twisting EFP waveform with variation in
polarity.
● Continuous changes in the excitation interval corresponding to twisting
changes of the EFP waveform. When meandering of the wave center occurs,
the motion of wave center chronologically changes the distance between wave
center and each electrode, which leads to the continuous changes in excitation
interval.
Motion vector prediction (MVP) analysis. We used a high-precision live cell
motion imaging system (Motion Vector Prediction; Sony, Tokyo, Japan). We
recorded the movies in a resolution of 2048 × 2048 pixels and adjusted the frame
rates in the range from 18 to 150 images per second. Motion vectors of beating cells
and CTSs were calculated using a block-matching algorithm41. From the processes
of motion detection and analysis, we obtained the deformation speed as positive
values. We measured the chronological ﬂuctuation of the motion vector of 262144
points consisting of 4 × 4 pixels as biphasic waveforms, which indicated contraction
and relaxation (Supplementary Fig. 7). We visualized the motion amplitude by
colour mapping all points included in the view ﬁeld and analyzed the two
dimensional propagation of cellular motion.
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Simultaneous recording of EFP and MVP. Simultaneous recordings of the
motion and EFP were performed using a stage top mini-incubator (INUSFP-MED-
F1-PT, Tokai Hit Co., Ltd., Shizuoka, Japan), which can maintain an MED probe in
a humidiﬁed atmosphere of 95% air / 5% CO2 at 37.0 °C. This mini-incubator was
placed on an inverted microscope (Eclipse Ti, Nikon) with an x−y scanning stage
(Bios-T, Sigma Koki, Tokyo, Japan). The MED probe was connected to an
ampliﬁer system (MED64 System). The round frequency was calculated from EFPs
related to spiral wave re-entry motion propagation in the MVP.
Membrane potential oscillation analysis. For membrane potential oscillation
analyses, CTSs were loaded with FluoVolt (Thermo Fisher Scientiﬁc) for 30 min.
FluoVolt ﬂuorescence (excitation at 535 nm and emission at 522 nm) of a beating
CTS was measured every 33 msec and visualized using Nikon A1R MP (Nikon).
Measurements were performed at 37 °C in an incubator system. E-4031 was
administered in the medium, and the membrane potential oscillation was recorded.
RNA extraction and quantitative reverse transcription polymerase chain
reaction (RT-PCR). Total RNA was extracted from cell sheets using RLT Lysis
buffer (QIAGEN Sciences, Maryland, USA) according to the manufacturer’s
instructions. We purchased human total heart RNA (Takara Bio Inc.). Reverse
transcription was performed with ReverTra Ace reverse transcriptase (TOYOBO
Co., Osaka, Japan). Quantitative RT-PCR was performed using TaqMan® Gene
Expression Master Mix (Thermo Fisher Scientiﬁc) according to the manufacturer’s
instructions. The amount of target RNA was determined with TaqMan® assays
(Thermo Fisher Scientiﬁc). RRN18S (18S ribosomal RNA) levels were used to
normalize the expression data for each gene of interest. The TaqMan® Assay IDs of
the target genes are shown below. Gene Symbol/Assay ID: SCN5A/
Hs00165693_m1, CACNA1C/Hs00167681_m1, KCNH2/Hs04234270_g1, KCNQ1/
Hs00923522_m1, KCNJ2/Hs01876357_s1, KCNJ12/Hs00266926_s1, TNNT2/
Hs00943911_m1, 18S rRNA/Hs99999901_s1, GAPDH/Hs02758991_g1.
Live/dead assay. A cell sheet was used to evaluate cell viability. To make cell
sheets, we used cardiomyocytes derived from the human iPSC line 836B3 (passage
30) and mesenchymal cells derived from the human iPSC line 201B6 (passage 41).
The cell sheets were incubated with staining solution (50 mL/L ethidium homo-
dimer I and 50 mL/L Hoechst 33342, PromoCell GmbH, Heidelberg, Germany) in
a pH-adjusted buffer for 30 min at room temperature and protected from light.
Fluorescent images were obtained using a microscope (Biorevo BZ-9000, Keyence,
Osaka, Japan). For several random areas under × 200 magniﬁcation, the numbers
of ethidium homodimer I-positive cells and Hoechst 33342-positive cells were
calculated with Biorevo BZ-9000 software.
HIF1α staining. The HIF1α staining of CTSs and cells was performed similarly to
the immunoﬂuorescence staining above. To make cell sheets, we used cardio-
myocytes derived from 836B3 (passage 30) and mesenchymal cells derived from
201B6 (passage 41). For normal culture, those cells were mixed and plated onto a
0.1% gelatine-coated 96-multiwell glass-bottom plates at 4.0 × 104 cells/well. An
antibody against HIF1α (GeneTex Irvine, USA 1:200) was used as the primary
antibody. Anti-rabbit Alexa 488 (Thermo Fisher Scientiﬁc) (1:400) was used as the
secondary antibody. The stained sheets and cells were photographed with Zeiss
LMS 700 (Carl Zeiss).
Statistical analysis. All data analyses were performed using JMP version 11.2.0
(SAS Institute, Cary, USA). Comparisons between two groups were made with
Wilcoxon signed-rank test. Comparisons among three or more groups were per-
formed using Steel’s test. Values are shown as the mean± s.d. Fisher’s exact test
was calculated to compare the induction rate. p-values < 0.05 were considered
signiﬁcant.
Data availability. All data supporting the ﬁndings of this study are either included
within the article and its Supplementary Information ﬁles or are available upon
request from the corresponding author.
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